Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Industri |
| Industri | Industriprodukter |
Acuvi AB today announces that its subsidiary Sensapex, part of its Life Science Instrumentation business unit (LSI), has introduced new turnkey solution to Neurotech market segment. It is a robotic workstation based on Sensapex micromanipulators and used to insert the latest microelectronic probes to brain in Neurosensing research applications. Main customer benefits include increased accuracy and stability, as well as better usability and scalability for very large-scale recordings.
The new solution has received high interest and positive feedbacks from customers during limited pre-marketing campaign. Close to 2 MSEK purchase orders have been received from pre-marketing and the first manufacturing series have been successfully completed in September.
"Sensapex has had the privilege to provide micromanipulators to world leading researchers involved in the development of latest microelectronics based probes such as Neuropixels for very large scale brain cell recordings. These technologies are now becoming increasingly available commercially for wide deployment in neuroscience research. Having worked with pioneers and opinion leaders, we have a strong starting position in this growing niche segment, which is also linked to the emerging medical Neurotech applications", says Mikko Vähäsöyrinki, VP of LSI.
The announced new solution is one of the growth initiatives in LSI strategy, which was created during the recent establishment of the business unit. Other LSI growth pillars include IVF market entry and expansion of Sensapex products based customized solutions to industrial customer segments.
"In general, Neurotech market is a very interesting segment for LSI. Based on market reports its size is currently USD 11-13 billion with estimated CAGR of 12-15 percent until 2030 with majority of today's business coming from well-established neurostimulation and neuroprosthese applications. Growth is driven by rising prevalence of neurological illness, high level of investments in neurotech industry and new technologies related to the brain-machine interfaces (BMI). Some of the new BMI technologies have already reached maturity level sufficient to start clinical testing and have potential to disrupt the Neurotech market", Vähäsöyrinki continues.
For more information, please contact:
Olof Stranding, CEO
ir@acuvi.com
Certified Adviser: Corpura Fondkommission AB
ca@corpura.se
+46 (0)72-252 34 51
About Acuvi
Acuvi is a group of companies that provides world-leading systems and technologies that enable higher precision and increased miniaturization. The customers can be found in, among other things, Life Science, the semiconductor industry and advanced optics. Acuvi's shares are traded on Nasdaq First North Growth Market.
www.acuvi.com
The information was submitted for publication by the above-mentioned contact person on 4 October 2023.